Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod

INTRODUCTION: While it is recommended that patients with multiple sclerosis (MS) be vaccinated against COVID-19, it is unknown what the vaccine response is in MS patients treated with fingolimod, an agent which modulates the humoral response. We aimed to characterize the immune response to the COVID...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciccone, A., Mathey, G., Prunis, C., Debouverie, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727589/
https://www.ncbi.nlm.nih.gov/pubmed/36496270
http://dx.doi.org/10.1016/j.neurol.2022.11.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727589/
https://www.ncbi.nlm.nih.gov/pubmed/36496270
http://dx.doi.org/10.1016/j.neurol.2022.11.003

Ejemplares similares